drugset / Trial / NCT02657486
BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to study the activity and effects of BGJ398 on bladder cancer tumors that are confined to the lining of the bladder.
Timeline
- Start
- 2016-01-06
- Primary completion
- 2026-02-04
- Completion
- 2026-02-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Infigratinib | Small molecule | 125 mg | Oral |